Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by TRAN, H. T. B.
Right arrow Articles by MILFORD, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by TRAN, H. T. B.
Right arrow Articles by MILFORD, E. L.
J Am Soc Nephrol 11:1903-1909, 2000
© 2000 American Society of Nephrology

Avoidance of Cyclosporine in Renal Transplantation

Effects of Daclizumab, Mycophenolate Mofetil, and Steroids

HUONG T. B. TRAN*,{ddagger}, MURALIDHAR K. ACHARYA*, DIANNE B. MCKAY*, MOHAMED H. SAYEGH*, CHARLES B. CARPENTER*, HUGH AUCHINCLOSS, JR.{dagger}, ROBERT L. KIRKMAN{dagger} and EDGAR L. MILFORD*

* Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
{dagger} Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
{ddagger} Department of Internal Medicine, Ho Chi Minh City University of Medicine and Pharmacy, Viet Nam.

Correspondence to Dr. Edgar L. Milford, Renal Division, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Phone: 617-732-5872; Fax: 617-566-6176; E-mail: emilford{at}rics.bwh.harvard.edu

Abstract. Cyclosporine (CsA) has been implicated in both acute and chronic graft dysfunction. The addition of humanized IL-2 receptor antibody daclizumab (DZB) to CsA-based immunosuppression decreases the rate of acute renal transplant rejection. Therefore, 45 patients were evaluated in an immunosuppressive protocol that included DZB, mycophenolate mofetil (MMF), and steroids without CsA. This was a prospective, nonrandomized, open-label trial of the efficacy and safety of the treatment. DZB was given intravenously at 2 mg/kg before transplantation and then at 1 mg/kg every 2 wk for four doses, MMF was given orally at 3 g/d, and methylprednisolone/prednisone was given at 7 mg/kg per day and tapered to 15 mg/d at 6 mo. CsA was added to the regimen when patients developed acute rejection episodes or adverse effects to steroids or MMF; 49% of patients were spared CsA maintenance. Patients without CsA had lower serum creatinine at 6 mo and needed fewer medications to control BP. Incidence of biopsyproven rejections was 31% and occurred early (median, 10 d). These rejection episodes occurred earlier in cadaver transplants (median, 7 d) and later in living donor transplants (median, 62 days). Acute rejections occurred at a higher frequency (46% versus 34%) and earlier (6.5 versus 15 d) in patients with delayed graft function compared with patients without delayed graft function. Most of the rejections were moderate and easily reversible. The actuarial 1-yr graft survival was 95% with 100% patient survival.




This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
A. F. Hamdy, M. A. Bakr, and M. A. Ghoneim
Long-term Efficacy and Safety of a Calcineurin Inhibitor-free Regimen in Live-Donor Renal Transplant Recipients
J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1225 - 1232.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
A. Djamali, M. Samaniego, B. Muth, R. Muehrer, R. M. Hofmann, J. Pirsch, A. Howard, G. Mourad, and B. N. Becker
Medical Care of Kidney Transplant Recipients after the First Posttransplant Year
Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 623 - 640.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. Woywodt, M. Schroeder, M. Mengel, A. Schwarz, W. Gwinner, H. Haller, and M. Haubitz
Circulating Endothelial Cells Are a Novel Marker of Cyclosporine-Induced Endothelial Damage
Hypertension, March 1, 2003; 41(3): 720 - 723.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Pascual, T. Theruvath, T. Kawai, N. Tolkoff-Rubin, and A. B. Cosimi
Strategies to Improve Long-Term Outcomes after Renal Transplantation
N. Engl. J. Med., February 21, 2002; 346(8): 580 - 590.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
P. GAUTHIER and J. H. HELDERMAN
Cyclosporine Avoidance
J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1933 - 1936.
[Full Text]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673